Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder

CNS Drugs

Volumn 25, Issue 1, 2011, Pages 17-36

  Ramos Quiroga, J Antoni ^a,b   Casas, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adolescents; Adults; Atomoxetine, therapeutic use; Attention deficit hyperactivity disorder, Children; Methylphenidate, therapeutic use.

Indexed keywords

ATOMOXETINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; PLACEBO;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED RELEASE FORMULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; OROSIRIAN; PRIORITY JOURNAL; RATING SCALE; REMISSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 78649964740     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11538450-000000000-00000     Document Type: Review

References (101)

1. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36 (2): 159-65.
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metare-gression analysis. Am J Psychiatry 2007 Jun; 164 (6): 942-8.
3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006 Apr; 163 (4): 716-23.
4. Barkley RA, Fischer M, Edelbrock CS, et al. The adoles- cent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990 Jul; 29 (4): 546-57.
5. Barkley RA, Fischer M, Edelbrock C, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 1991 Jan; 32 (2): 233-55.
6. Gittelman R, Mannuzza S, Shenker R, et al. Hyperactive boys almost grown up: I. Psychiatric status. Arch Gen Psychiatry 1985 Oct; 42 (10): 937-47.
7. DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998 Dec; 102 (6): 1415-21.
8. Willcutt EG, Pennington BF, Chhabildas NA, et al. Psy- chiatric comorbidity associated with DSM-IV ADHD in a nonreferred sample of twins. J Am Acad Child Adolesc Psychiatry 1999 Nov; 38 (11): 1355-62.
9. Biederman J, Faraone SV. The effects of attention-deficit/ hyperactivity disorder on employment and household income [abstract]. MedGenMed 2006; 8 (3): 12.
10. Biederman J, Petty CR, Fried R, et al. Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand 2007 Aug; 116 (2): 129-36.
11. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996 Dec; 98 (6 Pt 1): 1089-95.
12. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000 Apr; 61 (4): 244-51.
13. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hy-peractivity disorder. Br J Psychiatry 2007 May; 190: 402-9.
14. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006; 67 (4): 524-40.
15. Faraone SV, Buitelaar J. Comparing the efficacy of stim- ulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19 (4): 353-64.
16. Steele M, Jensen PS, Quinn DM. Remission versus re- sponse as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006 Nov; 28 (11): 1892-908.
17. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 2003; 64 Suppl. 15: 40-5.
18. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 Sep; 48 (9): 851-5.
19. Keck Jr PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hos-pitalization for a manic or mixed episode. Am J Psychiatry 1998 May; 155 (5): 646-52.
20. Andreasen NC, Carpenter Jr WT, Kane JM, et al. Remis- sion in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 Mar; 162 (3): 441-9.
21. American Psychiatric Association. Diagnostic and statis- tical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000.
22. Michelson D, Allen AJ, Busner J, et al. Once-daily atomox- etine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-901.
23. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily ato- moxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114 (1): e1-8.
24. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001 Aug; 58 (8): 775-82.
25. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomox-etine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-7.
26. Swanson JM. SNAP-IV Scale. Irvine (CA): Irvine Child Development Center, 1995.
27. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretations. New York: The Guilford Press, 1998.
28. NIMH National Institute of Mental Health. Clinical Glo- bal Impression Scale. Psychopharmacol Bull 1985; 21: 839-943.
29. American Psychiatric Association. Diagnostic and sta- tistical manual for mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
30. Murphy KR, Adler LA. Assessing attention-deficit/ hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry 2004; 65 Suppl. 3: 12-7.
31. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40 (2): 168-79.
32. Conners CK. Conners' rating scales, revised. Toronto (ON): Multi-Health Systems, 1997.
33. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35 (3): 343-51.
34. American Psychiatric Association. Diagnostic and statisical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000: 32-4.
35. Lambert NM, Hartsough CS, Sassone D, et al. Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes. Am J Orthopsychiatry 1987 Jan; 57 (1): 22-32.
36. Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. J Pediatr 1998 Oct; 133 (4): 544-51.
37. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles: an integrated system of multi-informant assessment. Burlington (VT): University of Vermont, Research Center for Children, Youth, and Families, 2001.
38. Weissman MM, Bothwell S. Assessment of social adjust- ment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111-5.
39. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000 May; 157 (5): 816-8.
40. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methyl-phenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006 Winter; 13 (1): e50-62.
41. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006 Nov; 45 (11): 1284-93.
42. Weiss M, Wasdell M, Patin J. A post hoc analysis of D-threo- methylphenidate hydrochloride (focalin) versus D,L-threo-methylphenidate hydrochloride (ritalin). J Am Acad Child Adolesc Psychiatry 2004 Nov; 43 (11): 1415-21.
43. Stein MA, Sarampote CS, Waldman ID, et al. A dose- response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003 Nov; 112 (5): e404.
44. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta- analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 209-18.
45. Hong H, Hong N, Yoon H, et al. Differences in the clinical characteristics of remission and non-remission groups with once-daily OROS-methylphenidate treatment of attention-deficit/hyperactivity disorder. Clin Psycho-pharmacol Neurosci 2008; 76 (1): 24-30.
46. Guy W. ECDEU: assessment manual for psychopharma- cology, revised. Rockville (MD): US Department of Health, Education and Welfare, 1976.
47. Kim YS, So YK, Choi NK, et al. Normative data on the Korean ADHD Rating Scales (K-ARS) for parents and teachers. J Korean Neuropsychiatr Assoc 2003; 42: 352-9.
48. Jacobson N, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-9.
49. Atzori P, Usala T, Carucci S, et al. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 2009 Dec; 19 (6): 673-81.
50. Okie S. ADHD in adults. N Engl J Med 2006 Jun 22; 354 (25): 2637-41.
51. Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994 May; 151 (5): 633-8.
52. Kessler RC, Adler LA, Barkley R, et al. Patterns and pre- dictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry 2005 Jun 1; 57 (11): 1442-51.
53. Andersen SL, Teicher MH. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Bio-behav Rev 2000 Jan; 24 (1): 137-41.
54. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002 May; 111 (2): 279-89.
55. Anderson JC, Williams S, McGee R, et al. DSM-III dis- orders in preadolescent children: prevalence in a large sample from the general population. Arch Gen Psychiatry 1987 Jan; 44 (1): 69-76.
56. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. Arch Gen Psychiatry 1988 Dec; 45 (12): 1120-6.
57. Tannock R. Attention deficit hyperactivity disorder: ad- vances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 1998 Jan; 39 (1): 65-99.
58. Semrud-Clikeman M, Filipek PA, Biederman J, et al. Attention-deficit hyperactivity disorder: magnetic resonance imaging morphometric analysis of the corpus callosum. J Am Acad Child Adolesc Psychiatry 1994 Jul-Aug; 33 (6): 875-81.
59. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genet- ics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005 Jun 1; 57 (11): 1313-23.
60. Fisher SE, Francks C, McCracken JT, et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet 2002 May; 70 (5): 1183-96.
61. Bakker SC, van der Meulen EM, Buitelaar JK, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003 May; 72 (5): 1251-60.
62. Arcos-Burgos M, Castellanos FX, Pineda D, et al. Atten- tion-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet 2004 Dec; 75 (6): 998-1014.
63. Hebebrand J, Dempfle A, Saar K, et al. A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Mol Psychiatry 2006 Feb; 11 (2): 196-205.
64. Ogdie MN, Bakker SC, Fisher SE, et al. Pooled genome- wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p13. Mol Psychiatry 2006 Jan; 11 (1): 5-8.
65. Faraone SV, Doyle AE, Lasky-Su J, et al. Linkage analysis of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008 Dec 5; 147B (8): 1387-91.
66. Asherson P, Zhou K, Anney RJ, et al. A high-density SNP linkage scan with 142 combined subtype ADHD sib pairs identifies linkage regions on chromosomes 9 and 16. Mol Psychiatry 2008 May; 13 (5): 514-21.
67. Romanos M, Freitag C, Jacob C, et al. Genome-wide linkage analysis of ADHD using high-density SNP arrays: novel loci at 5q13.1 and 14q12. Mol Psychiatry 2008 May; 13 (5): 522-30.
68. Zhou K, Dempfle A, Arcos-Burgos M, et al. Meta-analysis of genome-wide linkage scans of attention deficit hyper-activity disorder. Am J Med Genet B Neuropsychiatr Genet 2008 Dec 5; 147B (8): 1392-8.
69. Biederman J, Mick E, Faraone SV. Depression in attention deficit hyperactivity disorder (ADHD) children: "true" depression or demoralization? J Affect Disord 1998 Jan; 47 (1-3): 113-22.
70. Li J, Kang C, Wang Y, et al. Contribution of 5-HT2A receptor gene -1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents. Am J Med Genet B Neuropsychiatr Genet 2006 Jul 5; 141B (5): 473-6.
71. Li J, Kang C, Zhang H, et al. Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuro-psychiatr Genet 2007 Jun 5; 144B (4): 430-3.
72. Keck Jr PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hos-pitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646-52.
73. Ribases M, Hervas A, Ramos-Quiroga JA, et al. Associa- tion study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/ hyperactivity disorder. Biol Psychiatry 2008 May 15; 63 (10): 935-45.
74. Ribases M, Ramos-Quiroga JA, Hervas A, et al. Explo- ration of 19 serotoninergic candidate genes in adults and children with attention-deficit/ hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 2007; 14 (1): 71-85.
75. Hamarman S, Fossella J, Ulger C, et al. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psy-chopharmacology 2004 Winter; 14 (4): 564-74.
76. Biederman J, Petty CR, Ten Haagen KS, et al. Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatry Res 2009 Dec 30; 170 (2-3): 199-203.
77. Schulz KP, Newcorn JH, Fan J, et al. Brain activation gradients in ventrolateral prefrontal cortex related to persistence of ADHD in adolescent boys. J Am Acad Child Adolesc Psychiatry 2005 Jan; 44 (1): 47-54.
78. Shaw P, Lerch J, Greenstein D, et al. Longitudinal map- ping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2006 May; 63 (5): 540-9.
79. Shaffer D, Gould MS, Brasic J, et al. A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228-31.
80. Mick E, Faraone S, Biederman J. Age-dependent expres- sion of attention-deficit/hyperactivity disorder symptoms. Psychiatr Clin N Am 2004; 27: 215-24.
81. Faraone SV, Biederman J, Monuteaux MC. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol 2000 Jan; 18 (1): 1-16.
82. The MTA Cooperative Group. A 14-month randomised clinical trial of treatment of strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-86.
83. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2001 Nov; 40 (11): 1352-5.
84. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003 Feb; 60 (2): 204-11.
85. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: 17-30.
86. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once- a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001 Jun; 107 (6): e105.
87. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Pediatr Drugs 2003; 5 (12): 833-41.
88. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003 Jan; 111 (1): 179-85.
89. Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009 Dec; 57 (7-8): 640-52.
90. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Pediatr Drugs 2008; 10 (1): 39-47.
91. Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin 2008 Feb; 24 (2): 449-60.
92. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008; 22 (7): 603-11.
93. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV infected patients: the GEEMA Study. AIDS 2002; 16 (4): 605-13.
94. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993 Mar; 32 (2): 361-8.
95. Biederman J, Newcorn J, Sprich S. Comorbidity of atten- tion deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 May; 148 (5): 564-77.
96. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002 Nov; 22 (8): 1107-31.
97. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 2003 Apr; 39 (3): 180-5.
98. Spencer T, Biederman J, Wilens T, et al. A large, double- blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005 Mar 1; 57 (5): 456-63.
99. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyper-activity disorder. Drug Saf 2008; 31 (4): 345-54.
100. Wernicke J, Faries D, Girod D, et al. Cardiovascular ef- fects of atomoxetine in children, adolescents and adults. Drug Saf 2003; 26 (10): 729-40.
101. Committee for Medicinal Products for Human Use. Questions and answers on the review of medicines containing methylphenidate [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/ Methylphenidate-31/WC500011125. pdf [Accessed 2010 Oct 27]